Charles H. Nightingale

Author

Also Known As

C H Nightingale, C Nightingale, CHARLES H. NIGHTINGALE, CHARLES NIGHTINGALE, Charles H Nightingale, Charles H. Nightingale, Charles Nightingale, Charles H. Nightingale

256

Publications

6.4K

Citations

H-Index

133

Concepts

All Affiliations

Hartford Hospital Hartford Financial Services (United States)University of Connecticut Office of Infectious Diseases Pharmacy Research UK

About

Charles H. Nightingale is an author at Hartford Hospital specializing in medicine, pharmacology, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	73	2.4K
2	Health Sciences	16	20	710
3	Engineering	2	2	97
4	Arts	1	1	16
5	Business	1	1	39

Charles H. Nightingale

121

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against <i>Streptococcus pneumoniae</i> in an In Vitro Model of Infection Melinda K. Lacy, Wen Lu, Xiaowei Xu, Antimicrobial Agents and Chemotherapy	1999	217
Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem Joseph L. Kuti, Prachi K. Dandekar, Charles H. Nightingale, The Journal of Clinical Pharmacology	2003	196
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, The Journal of Clinical Pharmacology	2006	166
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia David P. Nicolau, JoCarol McNabb, Melinda K. Lacy, International Journal of Antimicrobial Agents Klebsiella PneumoniaePatient SafetyAcute CareSepsisNosocomial Pneumonia	2001	157
Adherence to Highly Active Antiretroviral Therapy Predicts Virologic Outcome at an Inner‐City Human Immunodeficiency Virus Clinic JoCarol McNabb, Jack Ross, Kenneth Abriola, Clinical Infectious Diseases Sexual HealthEpidemiologyPreventive MedicineInjection Drug UsersTreatment And Prevention	2001	154
Physiologically Based Pharmacokinetic Model for β-Lactam Antibiotics I: Tissue Distribution and Elimanation Rates Akira Tsuji, Takayoshi Yoshikawa, KAZUNORI NISHIDE, Journal of Pharmaceutical Sciences Pharmacokinetic ModelingPharmacodynamicsAntibioticsβ-Lactam AntibioticsPharmacology	1983	145
Impact of Extended-Spectrum <i>β</i> -Lactamase–Producing <i>Escherichia coli</i> and <i>Klebsiella</i> Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study Su Young Lee, Srividya Kotapati, Joseph L. Kuti, Infection Control and Hospital Epidemiology	2006	142
Clinical Efficacy and Pharmacoeconomics of a Continuous‐Infusion Piperacillin‐Tazobactam Program in a Large Community Teaching Hospital Edward M. Grant, Joseph L. Kuti, David P. Nicolau, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2002	127
Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, Journal of Antimicrobial Chemotherapy	2005	112
Cost Effect of Managing Methicillin‐Resistant <i>Staphylococcus Aureus</i> in a Long‐Term Care Facility Blair Capitano, Osnat Alice Leshem, Charles H. Nightingale, Journal of the American Geriatrics Society	2003	104

Page 1